LBVD is under clinical development by LG Chem and currently in Phase II for Poliomyelitis. According to GlobalData, Phase II drugs for Poliomyelitis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LBVD’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LBVD is under development for the prevention of diphtheria, tetanus, pertussis (whooping cough), hepatitis B, meningitis and poliomyelitis. It is administered by the intramuscular route. The vaccine candidate is a fully liquid hexavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-poliomyelitis (inactivated)-Haemophilus influenzae type B conjugate (DTwP-HepB-IPV-Hib) vaccine.
LG Chem overview
LG Chem, a subsidiary of LG Corp, is a chemical manufacturer. The company manufactures and markets petrochemicals, IT and electronic materials, and energy solutions. Its product portfolio comprises polyvinyl chloride (PVC), ethylene, propylene, butadiene, benzene, polarizer, glass substrate, semiconductor materials and RO membranes, among others. It also offers growth hormone, vaccine, anti-diabetic products, and manufactures and supplies display and battery materials for LCD photoresist, OLED materials, battery materials and others. It owns and operates manufacturing facilities in Daesan, Yeosu, Ochang, Cheongju, Ulsan, Naju, Iksan, Paju and Gimcheon. The company has operations in China, India, Germany, the US, Vietnam, Brazil, Taiwan, Hong Kong and Poland, among others. LG Chem is headquartered in Seoul, South Korea.
For a complete picture of LBVD’s drug-specific PTSR and LoA scores, buy the report here.